nejm semaglutide cardiovascular New in the August 14, 2025, issue of NEJM: ⁣ ⁣ Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial)⁣ ⁣ Cagrilintide– for Overweight and Diabetes (REDEFINE 2 phase 3a trial)⁣ ⁣ soul trial oral semaglutide cardiovascular

In the near term, employers face continued pressure to respond to employee demand while managing rapidly rising pharmacy costs

These medications have attracted significant attention for their ability to support weight loss, improve metabolic health, and help individuals struggling with obesity

Research shows that people who take Wegovy and make lifestyle changes can lose an average of about 15 percent of their body weight over 68 weeks

Some people prefer to let it reach room temperature for a few minutes first to reduce discomfort, but it is safe either way.

More importantly, if chronic fatigue and low energy are your norm, its time to check in with a doc since it may be a hormonal-based thyroid issue or a nutritional deficiency like anemia, she adds